
Life Sciences
BridgeBio to Present Phase 3 Encaleret Data at Boston Bone Meeting
The company's results in autosomal dominant hypocalcemia type 1 are scheduled for two oral presentations on October 11 at the Boston gathering.
Boston Business Watch reported on Indiana University School of Medicine on October 7, 2026.
October 7, 2026
Two oral presentations are scheduled for October 11: 24-week data on mineral balance and bone turnover, to be delivered by Erik A. Imel of Indiana University School of Medicine, and findings on patient-reported symptoms and treatment experience, to be delivered by Steven W. Ing of Ohio State University Wexner Medical Center.

Life Sciences
The company's results in autosomal dominant hypocalcemia type 1 are scheduled for two oral presentations on October 11 at the Boston gathering.